2013 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/25/13MyoKardia Appoints Biotech Veteran Mark L. Perry to Board of Directors
SOUTH SAN FRANCISCO, Calif. – November 25, 2013 – MyoKardia, Inc, a company focused on developing innovative therapeutics to treat genetic heart disease, today announced the appointment of Mark L. Perry to its board of directors, joining Tassos Gianakakos, Charles Homcy, M.D., and Kevin Starr. “With more than 30 years of biotechnology experience, Mark brings a wealth of expertise to MyoKardia as we evolve into a fully integrated development company focused on transforming cardiovascular care... 
10/30/13MyoKardia Appoints Tassos Gianakakos to Chief Executive Officer
South San Francisco – October 30, 2013 – MyoKardia, Inc, a company focused on developing innovative therapeutics to treat genetic heart disease, today announced the appointment of Tassos Gianakakos to chief executive officer. Mr. Gianakakos succeeds founding CEO Charles Homcy, M.D., who will remain on MyoKardia’s board of directors. “I am delighted to welcome Tassos to the MyoKardia team given his track record of growing and transforming research-stage organizations with meaningful drug plat... 
01/30/13MyoKardia Appoints Industry Veteran Jonathan Fox, M.D., Ph.D.,as Chief Medical Officer
South San Francisco – January 30, 2013 – MyoKardia, Inc, a company focused on developing innovative therapeutics to treat genetic cardiovascular disease, today announced the appointment of Jonathan C. Fox, M.D., Ph.D., as Chief Medical Officer. In his role, Dr. Fox will be responsible for the clinical development and regulatory strategy for MyoKardia’s pipeline of novel, small molecule therapeutics focused on treatments for genetically determined hypertrophic cardiomyopathy (HCM) and dilated car...